Dupilumab on Airway Hyper-responsiveness and Ventilation Heterogeneity in Patients With Asthma.

Asthma Clinical Trial

Official title:

A Two-arm, Placebo-controlled Randomized Clinical Trial to Evaluate the Effect of Dupilumab on Airway Hyper-responsiveness and Ventilation Heterogeneity in Patients With Asthma With a "T2 Immune Signature"

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03884842
• Other study ID #: 11963
• Status: Completed
• Phase: Phase 3
• Start date: July 1, 2019
• Est. completion date: January 17, 2023

Study information

• Verified date: January 2023
• Source: McMaster University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

In asthmatics with airway hyperresponsiveness and a "T2 immune signature" (type 2), Dupilumab will suppress airway hyperresponsiveness (assessed by methacholine PC20 ≤ 4 mg/mL (PC20: provocative concentration causing a 20% fall in FEV1) OR ≥15% decreased in forced expired volume in 1 second (FEV1) during saline inhalation for sputum induction OR ≥25% improvement in FEV1 after bronchodilator) and airway eosinophilia (assessed by sputum eosinophils) and this will be associated with greater asthma control and improved ventilation heterogeneity.

Description:

Along with these features of eosinophil recruitment, degranulation and autoantibody generation, that are partly dependent on (interleukin-4) IL-4 and (interleukin-13) IL-13 signalling, two additional characteristic features of asthma ie airway hyperresponsiveness and mucus hypersecretion are also determined by IL-13 biology. Neither of these important features have been investigated in any clinical trials of anti-IL-13 molecules. Accurate endotyping to identify patients in whom IL-13 mediated biology is the dominant pathobiology of asthma (selecting patients with significant airway hyperresponsiveness and mucus secretion) may elicit greater clinical effect. Taken together, we propose to investigate the effects of Dupilumab on airway hyperresponsiveness, on airway eosinophilia and mucus biology and their relation to airway structure and function (ventilation heterogeneity), and airway autoimmune responses.

To satisfy the proposed objective we will evaluate well-established outcome measures of airway hyperresponsiveness (provocation concentration of methacholine causing a 20% fall in FEV1 (PC20), type 2 inflammation (sputum eosinophils, blood eosinophils and exhaled nitric oxide (eNO)) and mucus biology.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 24
• Est. completion date: January 17, 2023
• Est. primary completion date: October 12, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• General

1. Able and willing to provide written informed consent.

2. Able and willing to comply with the study protocol.

3. Males and females = 18 years of age.

Asthma-related

4. Asthma diagnosed by a respiratory physician = 12 months prior to study enrolment based on the Global Initiative for Asthma (GINA) 2014 guidelines.

5. ACQ > 1 during the screening period.

6. Airway hyperresponsiveness (methacholine PC20 = 4 mg/mL OR =15% decreased in FEV1 during saline inhalation for sputum induction OR =25% improvement in FEV1 after bronchodilator) during the screening period.

7. Fraction of exhaled nitric oxide (FeNO) >25 ppb and either =3% sputum eosinophils (preferred) OR blood eos =300/µL during the screening period.

8. Inhaled corticosteroids (ICS) dose =500 mcg of fluticasone equivalent/day. Patients on prednisone would not be excluded as long as they meet the rest of the inclusion criteria.

Exclusion Criteria:

• Patients who meet any of the following criteria will be excluded from study entry:

Prior Medical Conditions and Treatment History

1. Acute or chronic parasitic, bacterial, fungal or viral infections that required, or currently requires, hospitalization or antimicrobial treatment during the last four weeks.

2. Acute asthma exacerbation event treated with increased doses of oral, or any dose of intramuscular (IM) or intravenous (IV) corticosteroids within six weeks prior to screening.

3. Other relevant pulmonary diseases (e.g. chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, cystic fibrosis, pulmonary arterial hypertension, tuberculosis) requiring treatment within 12 months prior to screening.

4. Alcohol or substance abuse within 12 months prior to screening.

5. Current smoker defined as having smoked at least one cigarette (or pipe, cigar, or marijuana) per day for = 30 days within the three months prior to screening.

6. Ex-smokers with = 10 pack-year smoking history.

7. Treatment with anti-IgE (immunoglobulin E), anti-IL-4, anti-IL-5 (interleukin-5), or anti-IL-13 targeted therapy currently or within three months prior to screening.

8. ACQ > 3.0

MRI (Magnetic Resonance Imaging )Related

9. Patient has an implanted mechanically, electrically or magnetically activated device or any metal in their body which cannot be removed, including but not limited to pacemakers, neurostimulators, biostimulators, implanted insulin pumps, aneurysm clips, bioprosthesis, artificial limb, metallic fragment or foreign body, shunt, surgical staples (including clips or metallic sutures and/or ear implants) (at the discretion of the MRI Technologist).

10. In the investigator's opinion, subject suffers from any physical, psychological or other condition(s) that might prevent performance of the MRI, such as severe claustrophobia.

General

11. Participation in any clinical trial of an investigational agent or procedure within six months prior to screening or during the study.

Related Conditions & MeSH terms

• Asthma
• Respiratory Hypersensitivity

Intervention

Biological:
• Dupilumab/Dupixent
a monoclonal antibody designed for the treatment asthma and atopic dermatitis.
• Placebo
Matched placebo

Locations

Country	Name	City	State
Canada	Firestone Institute for Respiratory Health, St. Joseph's Healthcare	Hamilton	Ontario

Sponsors (2)

Lead Sponsor	Collaborator
McMaster University	Sanofi

Country where clinical trial is conducted

Canada, 

References & Publications (3)

Crapo RO, Casaburi R, Coates AL, Enright PL, Hankinson JL, Irvin CG, MacIntyre NR, McKay RT, Wanger JS, Anderson SD, Cockcroft DW, Fish JE, Sterk PJ. Guidelines for methacholine and exercise challenge testing-1999. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. Am J Respir Crit Care Med. 2000 Jan;161(1):309-29. doi: 10.1164/ajrccm.161.1.ats11-99. No abstract available. — View Citation

Svenningsen S, Kirby M, Starr D, Leary D, Wheatley A, Maksym GN, McCormack DG, Parraga G. Hyperpolarized (3) He and (129) Xe MRI: differences in asthma before bronchodilation. J Magn Reson Imaging. 2013 Dec;38(6):1521-30. doi: 10.1002/jmri.24111. Epub 2013 Apr 15. — View Citation

Wills-Karp M, Luyimbazi J, Xu X, Schofield B, Neben TY, Karp CL, Donaldson DD. Interleukin-13: central mediator of allergic asthma. Science. 1998 Dec 18;282(5397):2258-61. doi: 10.1126/science.282.5397.2258. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Change in MRI ventilation heterogeneity (n=12 in each arm).	Change in MRI ventilation heterogeneity seen with administration of Hyperpolarized Xenon-129 inhalation.	Between randomization (week 0) and week 16.
Other	Change in CT airway remodeling and airway mucus scores (n=12 in each arm).	Changes are evaluated via CT inspiratory/expiratory scans via quantitative software (n=12 in each arm)	Between randomization (week 0) and week 16.
Primary	Proportion of patients that achieve at least one doubling dose improvement in PC20 methacholine and/or a 50% reduction in FEV1 reversibility after bronchodilator.	For patients that can undergo a methacholine challenge, one doubling dose improvement in PC20 methacholine. For those that cannot undergo a methacholine challenge a 50% reduction in FEV1 reversibility.	Between screening (week -4) and week 16.
Secondary	Change in geometric mean PC20 methacholine.	Change in PC20 between screening and week 16.	Between screening (week -4) and week 16.
Secondary	Change in FEV1 reversibility.	Change in FEV1 % reversibility (pre/post bronchodilator) between randomization and end of treatment.	Between randomization (week 0) and week 16.
Secondary	Change in sputum eosinophil percentage (%)	Change in sputum eosinophil percentage between randomization and end of treatment	Between randomization (week 0) and week 16.
Secondary	Change in blood eosinophil count	Change in blood eosinophil count levels between randomization and end of treatment	Between randomization (week 0) and week 16.
Secondary	Change in fraction of exhaled nitric oxide (FeNO)	Change in FeNO values parts per billion (ppb) from randomization and end of treatment.	Between randomization (week 0) and week 16.
Secondary	Change in FEV1 (pre-bronchodilator)	Change in pre-bronchodilator FEV1 values (in litres) between randomization and end of treatment.	Between randomization (week 0) and week 16.
Secondary	Change in Asthma Control Questionnaire-5 (ACQ-5)	Change in ACQ scores between randomization and end of treatment.	Between randomization (week 0) and week 16.
Secondary	Change in Asthma Control Questionnaire-5 (AQLQ)	Change in AQLQ scores between randomization and end of treatment.	Between randomization (week 0) and week 16.
Secondary	Change in Asthma Control Test (ACT)	Change in ACT scores between randomization and end of treatment.	Between randomization (week 0) and week 16.